Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study

The Lancet

Volumn 395, Issue 10221, 2020, Pages 361-369

  DeVito, Nicholas J ^a   Bacon, Seb ^a   Goldacre, Ben ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DATA EXTRACTION; GOVERNMENT; LAW; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; PUBLIC REPORTING (HEALTH CARE); QUALITY CONTROL; TIME; TREND STUDY; UNITED STATES; CLINICAL TRIAL (TOPIC); COOPERATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERPERSONAL COMMUNICATION; LEGISLATION AND JURISPRUDENCE; MEDICAL RESEARCH; REGISTER; RESEARCH;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COOPERATIVE BEHAVIOR; DISCLOSURE; HUMANS; REGISTRIES; RESEARCH REPORT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85078481729     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)33220-9     Document Type: Article

References (36)

1. Moher, D, Glasziou, P, Chalmers, I, et al. Increasing value and reducing waste in biomedical research: who's listening?. Lancet 387 (2016), 1573–1586.
2. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310 (2013), 2191–2194.
3. WHO. WHO statement on public disclosure of clinical trial results. http://www.who.int/ictrp/results/WHO_Statement_results_reporting_clinical_trials.pdf, April 14, 2015. (Accessed 9 January 2020)
4. Dwan, K, Gamble, C, Williamson, PR, Kirkham, JJ, Systematic review of the empirical evidence of study publication bias and outcome reporting bias—an updated review. PLoS One, 8, 2013, e66844.
5. Schmucker, C, Schell, LK, Portalupi, S, et al. Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. PLoS One, 9, 2014, e114023.
6. Food and Drug Administration Amendments Act of 2007. https://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf, Sept 27, 2007. (Accessed 9 January 2020)
7. Commission guideline — guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. Official J Eur Union 55 (2012), 7–10.
8. Goldacre, B, DeVito, NJ, Heneghan, C, et al. Compliance with requirement to report results on the EU clinical trials register: cohort study and web resource. BMJ, 362, 2018, k3218.
9. Viergever, RF, Li, K, Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open, 5, 2015, e008932.
10. Philippidis, A, Top 10 pharma companies of 2019. GEN: Genetic Engineering and Biotechnology News. https://www.genengnews.com/a-lists/top-10-pharma-companies-of-2019/, Nov 18, 2019. (Accessed 9 December 2019)
11. Anderson, ML, Chiswell, K, Peterson, ED, Tasneem, A, Topping, J, Califf, RM, Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 372 (2015), 1031–1039.
12. Prayle, AP, Hurley, MN, Smyth, AR, Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ, 344, 2012, d7373.
13. Lassman, SM, Shopshear, OM, Jazic, I, Ulrich, J, Francer, J, Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States. BMJ Open, 7, 2017, e015110.
14. National Institutes of Health, US Department of Health and Human Services. Clinical trials registration and results information submission. Final Rule. Fed Regist 81 (2016), 64981–65157.
15. Zarin, DA, Tse, T, Sheehan, J, The proposed rule for U.S. clinical trial registration and results submission. N Engl J Med 372 (2015), 174–180.
16. Zarin, DA, Tse, T, Williams, RJ, Carr, S, Trial reporting in ClinicalTrials.gov—the Final Rule. N Engl J Med 375 (2016), 1998–2004.
17. DeVito, NJ, Bacon, S, Goldacre, B, FDAAA TrialsTracker: a live informatics tool to monitor compliance with FDA requirements to report clinical trial results. bioRxiv, 2019 published online Oct 18. DOI: 10.1101/266452 (preprint).
18. ClinicalTrials.gov. Checklist for evaluating whether a clinical trial or study is an applicable clinical trial (ACT) under 42 CFR 11.22(b) for clinical trials initiated on or after January 18, 2017. https://prsinfo.clinicaltrials.gov/ACT_Checklist.pdf (accessed Feb 2, 2018).
19. ClinicalTrials.gov. ClinicalTrials.gov protocol registration and results system: PRS user's guide. https://prsinfo.clinicaltrials.gov/prs-users-guide.html (accessed June 7, 2019).
20. Davidson-Pilon, C, Kalderstam, J, Zivich, P, et al. CamDavidsonPilon/lifelines: v0.22.0 (version v0.22.0). Zenodo, 2019 published online July 3. DOI:10.5281/zenodo.3267531.
21. DeVito, NJ, ebmdatalab/fdaaa_trends: code to assess compliance with FDAAA 2007 (version v1.0). Zenodo, 2020 published online Jan 9. DOI:10.5281/zenodo.3603491.
22. DeVito, NJ, FDAAA trends analysis. Open Science Framework, 2020 published online Jan 10. DOI:10.17605/OSF.IO/X8NBV.
23. Hartung, DM, Zarin, DA, Guise, J-M, McDonagh, M, Paynter, R, Helfand, M, Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med 160 (2014), 477–483.
24. Riveros, C, Dechartres, A, Perrodeau, E, Haneef, R, Boutron, I, Ravaud, P, Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med, 10, 2013, e1001566.
25. Tang, E, Ravaud, P, Riveros, C, Perrodeau, E, Dechartres, A, Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med, 13, 2015, 189.
26. Huser, V, Cimino, JJ, Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. PLoS One, 8, 2013, e68409.
27. Zarin, DA, Fain, KM, Dobbins, HD, Tse, T, Williams, RJ, 10-year update on study results submitted to ClinicalTrials.gov. N Engl J Med 381 (2019), 1966–1974.
28. Zou, CX, Becker, JE, Phillips, AT, et al. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials, 19, 2018, 581.
29. Rayi, A, Thompson, S, Gloss, D, Malhotra, K, Reporting bias in completed epilepsy intervention trials: a cross-sectional analysis. Epilepsy Res 143 (2018), 1–6.
30. Mayo-Wilson, E, Heyward, J, Keyes, A, et al. Clinical trial registration and reporting: a survey of academic organizations in the United States. BMC Med, 16, 2018, 60.
31. Liberati, A, An unfinished trip through uncertainties. BMJ, 328, 2004, 531.
32. Hemminki, E, Study of information submitted by drug companies to licensing authorities. BMJ 280 (1980), 833–836.
33. US Department of Health and Human Services. Annual civil monetary penalties inflation adjustment. Final Rule. Fed Regist 84 (2019), 59549–59567.
34. US Department of Health and Human Services. Civil money penalties relating to the ClinicalTrials.gov data bank: draft guidance for FDA staff, responsible parties, and submitters of certain applications and submissions to FDA. https://www.fda.gov/media/113361/download, Sept 21, 2018. (Accessed 9 January 2020)
35. Jacquet, J, Is shame necessary? New uses for an old tool. 2016, Vintage, New York, NY.
36. Grimshaw, JM, Ivers, N, Linklater, S, et al. Reinvigorating stagnant science: implementation laboratories and a meta-laboratory to efficiently advance the science of audit and feedback. BMJ Qual Saf 28 (2019), 416–423.